查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1193120

药物发现外包市场：按工作流程、治疗领域、药物类型、最终用户分类：2021-2031 年全球机会分析和行业预测

Drug Discovery Outsourcing Market By Workflow, By Therapeutic area, By Drug Type, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 251 Pages | 商品交期: 2-3个工作天内

价格

全球药物发现外包市场预计2021年将达到36亿美元，2031年将达到74亿美元，2022年至2031年将以7.5%的复合年增长率增长。

药物发现外包被定义为各种公司通过将部分工作转移给外部供应商来降低药物开发成本的技术。 外包在各个领域进行，从药物发现到商业化。 通过外包给专门从事药物商业化的第三方，您可以最大限度地提高药物的价值主张。 在药理学、製药学和生物技术等各个领域发现新药和药物的过程。

此外，合同研究组织 (CRO) 还为製药和生物技术公司提供各种药物发现研究服务。 製药公司现在将研发活动外包给私人合同研究组织 (CRO) 和学术研究机构，以减少药物开发时间和成本。

癌症、心血管疾病、糖尿病和高血压等慢性病的增加、药物发现研发活动的增加以及靶向药物治疗需求的激增是推动药物发现外包市场增长的主要因素。 例如，根据 IQVIA 2022 年 6 月的一份报告，2016 年肿瘤药物开发的试验数量达到 56% 的历史新高。 2021年全球首次上市肿瘤领域新活性物质30个，创历史新高，自2012年以来共上市159个。 因此，越来越多的研究活动将增加进行临床试验以在市场上推出新分子的需求，增加对外包服务提供商的需求，从而推动市场的增长。

此外，製药公司越来越多地采用外包服务以及越来越多的主要参与者作为新药发布的 CRO 预计也将推动市场增长。 例如，美国和欧洲有超过 1,000 家 CRO。 前 10 名公司约占行业收入的 40%。 然而，CRO将重点放在药物研发和临床试验支持上，可以有效加速新药上市。

然而，不仅成本高，药物失败的风险高，而且熟练专业人员的短缺阻碍了市场的增长。 另一方面，新兴国家癌症、遗传病和慢性病发病率的增加、老年人口的增加、有利的监管环境以及具有高质量数据的低成本熟练劳动力的可用性将有助于预测期内的市场增长。提供有利可图的机会

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特的五力分析
  • 主要公司的定位
  • 市场动态
    • 司机
    • 约束因素
    • 机会
  • COVID-19 影响分析

第 4 章药物发现外包市场：按工作流程

  • 概览
    • 市场规模和预测
  • 目标识别和筛选
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 目标验证和功能信息学
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 潜在客户识别和候选人优化
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 临床前开发
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 5 章药物发现外包市场：按治疗领域分类

  • 概览
    • 市场规模和预测
  • 呼吸系统
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 感染
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 肿瘤学
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 免疫学
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 血液学
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 循环区
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 中枢神经系统 (CNS)
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 消化系统
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 6 章药物发现外包市场：按药物类型分类

  • 概览
    • 市场规模和预测
  • 小分子药物
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 大分子
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 7 章药物发现外包市场：最终用户

  • 概览
    • 市场规模和预测
  • 製药公司、生物技术公司
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 学术机构
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 8 章药物发现外包市场：按地区

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机遇
    • 北美市场规模和预测：按工作流程
    • 北美市场规模和预测：按治疗领域
    • 北美市场规模和预测：按药物类型
    • 北美市场规模和预测：按最终用户分类
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机遇
    • 欧洲市场规模和预测：按工作流程
    • 欧洲市场规模和预测：按治疗领域
    • 欧洲市场规模和预测：按药物类型
    • 欧洲市场规模和预测：按最终用户分类
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 法国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲
  • 亚太地区
    • 主要趋势和机遇
    • 亚太市场规模和预测：按工作流程
    • 亚太市场规模和预测：按治疗领域
    • 亚太市场规模和预测：按药物类型
    • 亚太市场规模和预测：按最终用户分类
    • 亚太地区的市场规模和预测：按国家/地区分类
      • 日本
      • 中国
      • 澳大利亚
      • 印度
      • 韩国
      • 其他亚太地区
  • 拉美
    • 主要趋势和机遇
    • LAMEA 市场规模和预测：按工作流程
    • LAMEA 市场规模和预测：按治疗领域
    • LAMEA 市场规模和预测：按药物类型
    • LAMEA 市场规模和预测：按最终用户分类
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其余部分

第九章商业条件

  • 简介
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 主要发展

第十章公司简介

  • . Charles River Laboratories,
  • Curia Global Inc
  • Dr. Reddy's Laboratories
  • Dalton Pharma Service
  • Discover X Corporation
  • Laboratory Corporation of America Holdings
  • Merck & Co
  • Syngene International Ltd
  • Thermo Fisher Scientific, Inc.
  • TCG Life Science Pvt. Ltd
Product Code: A14914

The global Drug Discovery Outsourcing Market Size was valued at $3.6 billion in 2021 and is projected to reach $7.4 billion by 2031, growing at a CAGR of 7.5% from 2022 to 2031.. Drug discovery outsourcing is defined as a practice that is used by different companies to reduce the cost of drug development by transferring portions of work to outside suppliers. Outsourced activities can be carried out in various fields, right from drug discovery to the manufacturing of products. Outsourcing drug commercialization to a third-party service provider specializing in drug commercialization helps to ensure the maximization of a drug product's value proposition.  It is a procedure that is used to find new medicines or drugs in different fields such as pharmacology, pharmaceuticals, and biotechnology.

Moreover, drug discovery contract research organizations (CROs) are engaged in offering a range of research services on a contract basis to pharmaceutical and biotechnology companies for drug discovery. Pharmaceutical companies are now outsourcing their R&D activities to private contract research organizations (CROs) and academic research institutions to reduce drug development time and cost.

The key factors that drive the growth of the market are the rise in the prevalence of chronic diseases such as cancer, cardiovascular disease, diabetes, and high blood pressure; the increase in R&D activities for drug discovery, and the surge in demand for target drug therapy are the major factors that drive the growth of the drug discovery outsourcing market. For instance, according to the report published by IQVIA in June 2022, the number of trials in oncology drug development reached a historic high of 56% in 2016.  A record 30 oncology novel active substances were initially launched globally in 2021, and a total of 159 have been launched since 2012. Thus, the rise in the number of research activities increases the demand for performing clinical trials to launch new molecules in the market, which increases the demand for outsourcing service providers and hence boosts the growth of the market.

Furthermore, rise in the adoption of outsourcing services by pharmaceutical companies and the increase in the number of key players as CROs for the launch of novel drug therapies are anticipated to fuel the growth of the market. For instance, there are more than 1,000 CROs in the U.S. and Europe. The top 10 accounts for approximately 40% of industry sales. However, CROs have been focused on drug development and clinical trial support, where they can effectively speed the launch of a new drug in the market.

However, the high cost as well as the high risk of drug failure, along with the lack of skilled professionals, hamper the market's growth. Conversely, rising cases of cancer, genetic disease, & chronic disease; large geriatric population; a favorable regulatory environment; and the availability of low-cost skilled manpower with high-quality data in the developing countries are expected to provide a lucrative opportunity for the growth of the market during the forecast period. 

The drug discovery outsourcing market is segmented on the basis of workflow, therapeutic area, drug type, end user, and region. By workflow, it is fragmented into target identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, and others. By therapeutic area, it is classified into the respiratory system, infectious disease, oncology, immunology, hematology, cardiovascular, central nervous system, gastrointestinal, and others. By drug type, it is bifurcated into small molecules and large molecules. By end user, the market is categorized into pharmaceutical & biotechnology companies, academic institutes, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America accounted for a majority of the drug discovery outsourcing market share in 2021 and is anticipated to remain dominant during the forecast period. The drug discovery outsourcing market is mainly driven by the presence of well-established research facilities and a high prevalence rate of cancer & chronic diseases. Moreover, the availability of technologically advanced medical devices and the rise in the demand for target drug therapy techniques to cure cancer are contributing to the growth of the market in this region. Furthermore, an increasing number of key players involved in R&D activities for the discovery of novel drugs is expected to fuel market growth.

Asia-Pacific is expected to register the fastest CAGR during the forecast period. This is due to the availability of low-cost skilled manpower and high-quality clinical trial data and constantly improving healthcare infrastructure. In addition, the rapidly growing population, rising incidence of cancer & chronic disease, and improvement in the quality of healthcare facilities are set to drive the market in Asia-Pacific. This helps several key market players to invest in Asia-Pacific countries, which in turn, is further expected to contribute to the growth of the market.

The key players that operate in the drug discovery outsourcing market are Curia Global Inc, Charles River Laboratories Inc, Dr. Reddy's Laboratories, Discover X Corporation, Dalton Pharma Service, Laboratory Corporation of America Holdings, Merck & Co, Syngene International Ltd, TCG Life Science Pvt. Ltd, and Thermo Fisher Scientific.

Key Benefits For Stakeholders 

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the drug discovery outsourcing market analysis from 2021 to 2031 to identify the prevailing drug discovery outsourcing market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the drug discovery outsourcing market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes an analysis of the regional as well as global drug discovery outsourcing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Workflow

  • Target Validation and Functional Informatics
  • Lead Identification and Candidate Optimization
  • Preclinical Development
  • Others
  • Target Identification and Screening

By Therapeutic area

  • Cardiovascular
  • Central Nervous System (CNS)
  • Gastrointestinal
  • Others
  • Hematology
  • Respiratory system
  • Infectious disease
  • Oncology
  • Immunology

By Drug Type

  • Small Molecules
  • Large Molecules

By End User

  • Pharmaceutical and Biotechnology companies
  • Academic Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • . Charles River Laboratories,
    • Curia Global Inc
    • Dr. Reddy's Laboratories
    • Dalton Pharma Service
    • Discover X Corporation
    • Laboratory Corporation of America Holdings
    • Merck & Co
    • Syngene International Ltd
    • Thermo Fisher Scientific, Inc.
    • TCG Life Science Pvt. Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Target Identification and Screening
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Target Validation and Functional Informatics
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
  • 4.4 Lead Identification and Candidate Optimization
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country
  • 4.5 Preclinical Development
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market share analysis by country
  • 4.6 Others
    • 4.6.1 Key market trends, growth factors and opportunities
    • 4.6.2 Market size and forecast, by region
    • 4.6.3 Market share analysis by country

CHAPTER 5: DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Respiratory system
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Infectious disease
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country
  • 5.4 Oncology
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market share analysis by country
  • 5.5 Immunology
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market share analysis by country
  • 5.6 Hematology
    • 5.6.1 Key market trends, growth factors and opportunities
    • 5.6.2 Market size and forecast, by region
    • 5.6.3 Market share analysis by country
  • 5.7 Cardiovascular
    • 5.7.1 Key market trends, growth factors and opportunities
    • 5.7.2 Market size and forecast, by region
    • 5.7.3 Market share analysis by country
  • 5.8 Central Nervous System (CNS)
    • 5.8.1 Key market trends, growth factors and opportunities
    • 5.8.2 Market size and forecast, by region
    • 5.8.3 Market share analysis by country
  • 5.9 Gastrointestinal
    • 5.9.1 Key market trends, growth factors and opportunities
    • 5.9.2 Market size and forecast, by region
    • 5.9.3 Market share analysis by country
  • 6.0 Others
    • 6.0.1 Key market trends, growth factors and opportunities
    • 6.0.2 Market size and forecast, by region
    • 6.0.3 Market share analysis by country

CHAPTER 6: DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Small Molecules
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Large Molecules
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country

CHAPTER 7: DRUG DISCOVERY OUTSOURCING MARKET, BY END USER

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 Pharmaceutical and Biotechnology companies
    • 7.2.1 Key market trends, growth factors and opportunities
    • 7.2.2 Market size and forecast, by region
    • 7.2.3 Market share analysis by country
  • 7.3 Academic Institutes
    • 7.3.1 Key market trends, growth factors and opportunities
    • 7.3.2 Market size and forecast, by region
    • 7.3.3 Market share analysis by country
  • 7.4 Others
    • 7.4.1 Key market trends, growth factors and opportunities
    • 7.4.2 Market size and forecast, by region
    • 7.4.3 Market share analysis by country

CHAPTER 8: DRUG DISCOVERY OUTSOURCING MARKET, BY REGION

  • 8.1 Overview
    • 8.1.1 Market size and forecast
  • 8.2 North America
    • 8.2.1 Key trends and opportunities
    • 8.2.2 North America Market size and forecast, by Workflow
    • 8.2.3 North America Market size and forecast, by Therapeutic area
    • 8.2.4 North America Market size and forecast, by Drug Type
    • 8.2.5 North America Market size and forecast, by End User
    • 8.2.6 North America Market size and forecast, by country
      • 8.2.6.1 U.S.
      • 8.2.6.1.1 Key market trends, growth factors and opportunities
      • 8.2.6.1.2 Market size and forecast, by Workflow
      • 8.2.6.1.3 Market size and forecast, by Therapeutic area
      • 8.2.6.1.4 Market size and forecast, by Drug Type
      • 8.2.6.1.5 Market size and forecast, by End User
      • 8.2.6.2 Canada
      • 8.2.6.2.1 Key market trends, growth factors and opportunities
      • 8.2.6.2.2 Market size and forecast, by Workflow
      • 8.2.6.2.3 Market size and forecast, by Therapeutic area
      • 8.2.6.2.4 Market size and forecast, by Drug Type
      • 8.2.6.2.5 Market size and forecast, by End User
      • 8.2.6.3 Mexico
      • 8.2.6.3.1 Key market trends, growth factors and opportunities
      • 8.2.6.3.2 Market size and forecast, by Workflow
      • 8.2.6.3.3 Market size and forecast, by Therapeutic area
      • 8.2.6.3.4 Market size and forecast, by Drug Type
      • 8.2.6.3.5 Market size and forecast, by End User
  • 8.3 Europe
    • 8.3.1 Key trends and opportunities
    • 8.3.2 Europe Market size and forecast, by Workflow
    • 8.3.3 Europe Market size and forecast, by Therapeutic area
    • 8.3.4 Europe Market size and forecast, by Drug Type
    • 8.3.5 Europe Market size and forecast, by End User
    • 8.3.6 Europe Market size and forecast, by country
      • 8.3.6.1 Germany
      • 8.3.6.1.1 Key market trends, growth factors and opportunities
      • 8.3.6.1.2 Market size and forecast, by Workflow
      • 8.3.6.1.3 Market size and forecast, by Therapeutic area
      • 8.3.6.1.4 Market size and forecast, by Drug Type
      • 8.3.6.1.5 Market size and forecast, by End User
      • 8.3.6.2 France
      • 8.3.6.2.1 Key market trends, growth factors and opportunities
      • 8.3.6.2.2 Market size and forecast, by Workflow
      • 8.3.6.2.3 Market size and forecast, by Therapeutic area
      • 8.3.6.2.4 Market size and forecast, by Drug Type
      • 8.3.6.2.5 Market size and forecast, by End User
      • 8.3.6.3 UK
      • 8.3.6.3.1 Key market trends, growth factors and opportunities
      • 8.3.6.3.2 Market size and forecast, by Workflow
      • 8.3.6.3.3 Market size and forecast, by Therapeutic area
      • 8.3.6.3.4 Market size and forecast, by Drug Type
      • 8.3.6.3.5 Market size and forecast, by End User
      • 8.3.6.4 Italy
      • 8.3.6.4.1 Key market trends, growth factors and opportunities
      • 8.3.6.4.2 Market size and forecast, by Workflow
      • 8.3.6.4.3 Market size and forecast, by Therapeutic area
      • 8.3.6.4.4 Market size and forecast, by Drug Type
      • 8.3.6.4.5 Market size and forecast, by End User
      • 8.3.6.5 Spain
      • 8.3.6.5.1 Key market trends, growth factors and opportunities
      • 8.3.6.5.2 Market size and forecast, by Workflow
      • 8.3.6.5.3 Market size and forecast, by Therapeutic area
      • 8.3.6.5.4 Market size and forecast, by Drug Type
      • 8.3.6.5.5 Market size and forecast, by End User
      • 8.3.6.6 Rest of Europe
      • 8.3.6.6.1 Key market trends, growth factors and opportunities
      • 8.3.6.6.2 Market size and forecast, by Workflow
      • 8.3.6.6.3 Market size and forecast, by Therapeutic area
      • 8.3.6.6.4 Market size and forecast, by Drug Type
      • 8.3.6.6.5 Market size and forecast, by End User
  • 8.4 Asia-Pacific
    • 8.4.1 Key trends and opportunities
    • 8.4.2 Asia-Pacific Market size and forecast, by Workflow
    • 8.4.3 Asia-Pacific Market size and forecast, by Therapeutic area
    • 8.4.4 Asia-Pacific Market size and forecast, by Drug Type
    • 8.4.5 Asia-Pacific Market size and forecast, by End User
    • 8.4.6 Asia-Pacific Market size and forecast, by country
      • 8.4.6.1 Japan
      • 8.4.6.1.1 Key market trends, growth factors and opportunities
      • 8.4.6.1.2 Market size and forecast, by Workflow
      • 8.4.6.1.3 Market size and forecast, by Therapeutic area
      • 8.4.6.1.4 Market size and forecast, by Drug Type
      • 8.4.6.1.5 Market size and forecast, by End User
      • 8.4.6.2 China
      • 8.4.6.2.1 Key market trends, growth factors and opportunities
      • 8.4.6.2.2 Market size and forecast, by Workflow
      • 8.4.6.2.3 Market size and forecast, by Therapeutic area
      • 8.4.6.2.4 Market size and forecast, by Drug Type
      • 8.4.6.2.5 Market size and forecast, by End User
      • 8.4.6.3 Australia
      • 8.4.6.3.1 Key market trends, growth factors and opportunities
      • 8.4.6.3.2 Market size and forecast, by Workflow
      • 8.4.6.3.3 Market size and forecast, by Therapeutic area
      • 8.4.6.3.4 Market size and forecast, by Drug Type
      • 8.4.6.3.5 Market size and forecast, by End User
      • 8.4.6.4 India
      • 8.4.6.4.1 Key market trends, growth factors and opportunities
      • 8.4.6.4.2 Market size and forecast, by Workflow
      • 8.4.6.4.3 Market size and forecast, by Therapeutic area
      • 8.4.6.4.4 Market size and forecast, by Drug Type
      • 8.4.6.4.5 Market size and forecast, by End User
      • 8.4.6.5 South Korea
      • 8.4.6.5.1 Key market trends, growth factors and opportunities
      • 8.4.6.5.2 Market size and forecast, by Workflow
      • 8.4.6.5.3 Market size and forecast, by Therapeutic area
      • 8.4.6.5.4 Market size and forecast, by Drug Type
      • 8.4.6.5.5 Market size and forecast, by End User
      • 8.4.6.6 Rest of Asia-Pacific
      • 8.4.6.6.1 Key market trends, growth factors and opportunities
      • 8.4.6.6.2 Market size and forecast, by Workflow
      • 8.4.6.6.3 Market size and forecast, by Therapeutic area
      • 8.4.6.6.4 Market size and forecast, by Drug Type
      • 8.4.6.6.5 Market size and forecast, by End User
  • 8.5 LAMEA
    • 8.5.1 Key trends and opportunities
    • 8.5.2 LAMEA Market size and forecast, by Workflow
    • 8.5.3 LAMEA Market size and forecast, by Therapeutic area
    • 8.5.4 LAMEA Market size and forecast, by Drug Type
    • 8.5.5 LAMEA Market size and forecast, by End User
    • 8.5.6 LAMEA Market size and forecast, by country
      • 8.5.6.1 Brazil
      • 8.5.6.1.1 Key market trends, growth factors and opportunities
      • 8.5.6.1.2 Market size and forecast, by Workflow
      • 8.5.6.1.3 Market size and forecast, by Therapeutic area
      • 8.5.6.1.4 Market size and forecast, by Drug Type
      • 8.5.6.1.5 Market size and forecast, by End User
      • 8.5.6.2 Saudi Arabia
      • 8.5.6.2.1 Key market trends, growth factors and opportunities
      • 8.5.6.2.2 Market size and forecast, by Workflow
      • 8.5.6.2.3 Market size and forecast, by Therapeutic area
      • 8.5.6.2.4 Market size and forecast, by Drug Type
      • 8.5.6.2.5 Market size and forecast, by End User
      • 8.5.6.3 South Africa
      • 8.5.6.3.1 Key market trends, growth factors and opportunities
      • 8.5.6.3.2 Market size and forecast, by Workflow
      • 8.5.6.3.3 Market size and forecast, by Therapeutic area
      • 8.5.6.3.4 Market size and forecast, by Drug Type
      • 8.5.6.3.5 Market size and forecast, by End User
      • 8.5.6.4 Rest of LAMEA
      • 8.5.6.4.1 Key market trends, growth factors and opportunities
      • 8.5.6.4.2 Market size and forecast, by Workflow
      • 8.5.6.4.3 Market size and forecast, by Therapeutic area
      • 8.5.6.4.4 Market size and forecast, by Drug Type
      • 8.5.6.4.5 Market size and forecast, by End User

CHAPTER 9: COMPANY LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Key developments

CHAPTER 10: COMPANY PROFILES

  • 10.1 . Charles River Laboratories,
    • 10.1.1 Company overview
    • 10.1.2 Company snapshot
    • 10.1.3 Operating business segments
    • 10.1.4 Product portfolio
    • 10.1.5 Business performance
    • 10.1.6 Key strategic moves and developments
  • 10.2 Curia Global Inc
    • 10.2.1 Company overview
    • 10.2.2 Company snapshot
    • 10.2.3 Operating business segments
    • 10.2.4 Product portfolio
    • 10.2.5 Business performance
    • 10.2.6 Key strategic moves and developments
  • 10.3 Dr. Reddy's Laboratories
    • 10.3.1 Company overview
    • 10.3.2 Company snapshot
    • 10.3.3 Operating business segments
    • 10.3.4 Product portfolio
    • 10.3.5 Business performance
    • 10.3.6 Key strategic moves and developments
  • 10.4 Dalton Pharma Service
    • 10.4.1 Company overview
    • 10.4.2 Company snapshot
    • 10.4.3 Operating business segments
    • 10.4.4 Product portfolio
    • 10.4.5 Business performance
    • 10.4.6 Key strategic moves and developments
  • 10.5 Discover X Corporation
    • 10.5.1 Company overview
    • 10.5.2 Company snapshot
    • 10.5.3 Operating business segments
    • 10.5.4 Product portfolio
    • 10.5.5 Business performance
    • 10.5.6 Key strategic moves and developments
  • 10.6 Laboratory Corporation of America Holdings
    • 10.6.1 Company overview
    • 10.6.2 Company snapshot
    • 10.6.3 Operating business segments
    • 10.6.4 Product portfolio
    • 10.6.5 Business performance
    • 10.6.6 Key strategic moves and developments
  • 10.7 Merck & Co
    • 10.7.1 Company overview
    • 10.7.2 Company snapshot
    • 10.7.3 Operating business segments
    • 10.7.4 Product portfolio
    • 10.7.5 Business performance
    • 10.7.6 Key strategic moves and developments
  • 10.8 Syngene International Ltd
    • 10.8.1 Company overview
    • 10.8.2 Company snapshot
    • 10.8.3 Operating business segments
    • 10.8.4 Product portfolio
    • 10.8.5 Business performance
    • 10.8.6 Key strategic moves and developments
  • 10.9 Thermo Fisher Scientific, Inc.
    • 10.9.1 Company overview
    • 10.9.2 Company snapshot
    • 10.9.3 Operating business segments
    • 10.9.4 Product portfolio
    • 10.9.5 Business performance
    • 10.9.6 Key strategic moves and developments
  • 10.10 TCG Life Science Pvt. Ltd
    • 10.10.1 Company overview
    • 10.10.2 Company snapshot
    • 10.10.3 Operating business segments
    • 10.10.4 Product portfolio
    • 10.10.5 Business performance
    • 10.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET IDENTIFICATION AND SCREENING, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET IDENTIFICATION AND SCREENING, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET VALIDATION AND FUNCTIONAL INFORMATICS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET VALIDATION AND FUNCTIONAL INFORMATICS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. DRUG DISCOVERY OUTSOURCING MARKET FOR LEAD IDENTIFICATION AND CANDIDATE OPTIMIZATION, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. DRUG DISCOVERY OUTSOURCING MARKET FOR LEAD IDENTIFICATION AND CANDIDATE OPTIMIZATION, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. DRUG DISCOVERY OUTSOURCING MARKET FOR PRECLINICAL DEVELOPMENT, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. DRUG DISCOVERY OUTSOURCING MARKET FOR PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. DRUG DISCOVERY OUTSOURCING MARKET FOR RESPIRATORY SYSTEM, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. DRUG DISCOVERY OUTSOURCING MARKET FOR RESPIRATORY SYSTEM, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. DRUG DISCOVERY OUTSOURCING MARKET FOR INFECTIOUS DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. DRUG DISCOVERY OUTSOURCING MARKET FOR INFECTIOUS DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. DRUG DISCOVERY OUTSOURCING MARKET FOR ONCOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. DRUG DISCOVERY OUTSOURCING MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. DRUG DISCOVERY OUTSOURCING MARKET FOR IMMUNOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. DRUG DISCOVERY OUTSOURCING MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. DRUG DISCOVERY OUTSOURCING MARKET FOR HEMATOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. DRUG DISCOVERY OUTSOURCING MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. DRUG DISCOVERY OUTSOURCING MARKET FOR CARDIOVASCULAR, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. DRUG DISCOVERY OUTSOURCING MARKET FOR CARDIOVASCULAR, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. DRUG DISCOVERY OUTSOURCING MARKET FOR CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. DRUG DISCOVERY OUTSOURCING MARKET FOR CENTRAL NERVOUS SYSTEM (CNS), BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. DRUG DISCOVERY OUTSOURCING MARKET FOR GASTROINTESTINAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. DRUG DISCOVERY OUTSOURCING MARKET FOR GASTROINTESTINAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. DRUG DISCOVERY OUTSOURCING MARKET FOR SMALL MOLECULES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. DRUG DISCOVERY OUTSOURCING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. DRUG DISCOVERY OUTSOURCING MARKET FOR LARGE MOLECULES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. DRUG DISCOVERY OUTSOURCING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. DRUG DISCOVERY OUTSOURCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. DRUG DISCOVERY OUTSOURCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. DRUG DISCOVERY OUTSOURCING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. DRUG DISCOVERY OUTSOURCING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. DRUG DISCOVERY OUTSOURCING MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. UK DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. UK DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. UK DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. UK DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 91. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 92. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 93. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 94. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 95. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 96. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 97. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 98. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 99. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 100. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 101. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 102. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 103. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 104. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 105. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 106. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 107. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 108. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 109. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 110. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 111. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 112. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 113. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 114. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 115. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 116. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 117. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 118. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 119. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 120. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 121. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 122. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 123. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 124. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 125. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 126. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 127. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 128. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 129. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 130. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 131. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 132. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 133. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 134. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 135. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 136. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 137. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 138. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 139. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 140.. CHARLES RIVER LABORATORIES,: COMPANY SNAPSHOT
  • TABLE 141.. CHARLES RIVER LABORATORIES,: OPERATING SEGMENTS
  • TABLE 142.. CHARLES RIVER LABORATORIES,: PRODUCT PORTFOLIO
  • TABLE 143.. CHARLES RIVER LABORATORIES,: NET SALES
  • TABLE 144.. CHARLES RIVER LABORATORIES,: KEY STRATERGIES
  • TABLE 145.CURIA GLOBAL INC: COMPANY SNAPSHOT
  • TABLE 146.CURIA GLOBAL INC: OPERATING SEGMENTS
  • TABLE 147.CURIA GLOBAL INC: PRODUCT PORTFOLIO
  • TABLE 148.CURIA GLOBAL INC: NET SALES
  • TABLE 149.CURIA GLOBAL INC: KEY STRATERGIES
  • TABLE 150.DR. REDDY'S LABORATORIES: COMPANY SNAPSHOT
  • TABLE 151.DR. REDDY'S LABORATORIES: OPERATING SEGMENTS
  • TABLE 152.DR. REDDY'S LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 153.DR. REDDY'S LABORATORIES: NET SALES
  • TABLE 154.DR. REDDY'S LABORATORIES: KEY STRATERGIES
  • TABLE 155.DALTON PHARMA SERVICE: COMPANY SNAPSHOT
  • TABLE 156.DALTON PHARMA SERVICE: OPERATING SEGMENTS
  • TABLE 157.DALTON PHARMA SERVICE: PRODUCT PORTFOLIO
  • TABLE 158.DALTON PHARMA SERVICE: NET SALES
  • TABLE 159.DALTON PHARMA SERVICE: KEY STRATERGIES
  • TABLE 160.DISCOVER X CORPORATION: COMPANY SNAPSHOT
  • TABLE 161.DISCOVER X CORPORATION: OPERATING SEGMENTS
  • TABLE 162.DISCOVER X CORPORATION: PRODUCT PORTFOLIO
  • TABLE 163.DISCOVER X CORPORATION: NET SALES
  • TABLE 164.DISCOVER X CORPORATION: KEY STRATERGIES
  • TABLE 165.LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
  • TABLE 166.LABORATORY CORPORATION OF AMERICA HOLDINGS: OPERATING SEGMENTS
  • TABLE 167.LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
  • TABLE 168.LABORATORY CORPORATION OF AMERICA HOLDINGS: NET SALES
  • TABLE 169.LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES
  • TABLE 170.MERCK & CO: COMPANY SNAPSHOT
  • TABLE 171.MERCK & CO: OPERATING SEGMENTS
  • TABLE 172.MERCK & CO: PRODUCT PORTFOLIO
  • TABLE 173.MERCK & CO: NET SALES
  • TABLE 174.MERCK & CO: KEY STRATERGIES
  • TABLE 175.SYNGENE INTERNATIONAL LTD: COMPANY SNAPSHOT
  • TABLE 176.SYNGENE INTERNATIONAL LTD: OPERATING SEGMENTS
  • TABLE 177.SYNGENE INTERNATIONAL LTD: PRODUCT PORTFOLIO
  • TABLE 178.SYNGENE INTERNATIONAL LTD: NET SALES
  • TABLE 179.SYNGENE INTERNATIONAL LTD: KEY STRATERGIES
  • TABLE 180.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 181.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
  • TABLE 182.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
  • TABLE 183.THERMO FISHER SCIENTIFIC, INC.: NET SALES
  • TABLE 184.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES
  • TABLE 185.TCG LIFE SCIENCE PVT. LTD: COMPANY SNAPSHOT
  • TABLE 186.TCG LIFE SCIENCE PVT. LTD: OPERATING SEGMENTS
  • TABLE 187.TCG LIFE SCIENCE PVT. LTD: PRODUCT PORTFOLIO
  • TABLE 188.TCG LIFE SCIENCE PVT. LTD: NET SALES
  • TABLE 189.TCG LIFE SCIENCE PVT. LTD: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION
  • FIGURE 2.DRUG DISCOVERY OUTSOURCING MARKET,2021-2031
  • FIGURE 3.DRUG DISCOVERY OUTSOURCING MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.DRUG DISCOVERY OUTSOURCING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.DRUG DISCOVERY OUTSOURCING MARKET,BY WORKFLOW,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF TARGET IDENTIFICATION AND SCREENING DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF TARGET VALIDATION AND FUNCTIONAL INFORMATICS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF LEAD IDENTIFICATION AND CANDIDATE OPTIMIZATION DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF PRECLINICAL DEVELOPMENT DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 18.DRUG DISCOVERY OUTSOURCING MARKET,BY THERAPEUTIC AREA,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF RESPIRATORY SYSTEM DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF INFECTIOUS DISEASE DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ONCOLOGY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF IMMUNOLOGY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HEMATOLOGY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF CARDIOVASCULAR DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF OTHERS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 28.DRUG DISCOVERY OUTSOURCING MARKET,BY DRUG TYPE,2021(%)
  • FIGURE 29.COMPARATIVE SHARE ANALYSIS OF SMALL MOLECULES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 30.COMPARATIVE SHARE ANALYSIS OF LARGE MOLECULES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 31.DRUG DISCOVERY OUTSOURCING MARKET,BY END USER,2021(%)
  • FIGURE 32.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 33.COMPARATIVE SHARE ANALYSIS OF ACADEMIC INSTITUTES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 34.COMPARATIVE SHARE ANALYSIS OF OTHERS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 35.DRUG DISCOVERY OUTSOURCING MARKET BY REGION,2021
  • FIGURE 36.U.S. DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 37.CANADA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 38.MEXICO DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 39.GERMANY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 40.FRANCE DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 41.UK DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 42.ITALY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 43.SPAIN DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 44.REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 45.JAPAN DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 46.CHINA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 47.AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 48.INDIA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 49.SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 50.REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 51.BRAZIL DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 52.SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 53.SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 54.REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 55. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 56. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 57. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 58.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 59.COMPETITIVE DASHBOARD
  • FIGURE 60.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 61.. CHARLES RIVER LABORATORIES,.: NET SALES ($MILLION)
  • FIGURE 62.CURIA GLOBAL INC.: NET SALES ($MILLION)
  • FIGURE 63.DR. REDDY'S LABORATORIES.: NET SALES ($MILLION)
  • FIGURE 64.DALTON PHARMA SERVICE.: NET SALES ($MILLION)
  • FIGURE 65.DISCOVER X CORPORATION.: NET SALES ($MILLION)
  • FIGURE 66.LABORATORY CORPORATION OF AMERICA HOLDINGS.: NET SALES ($MILLION)
  • FIGURE 67.MERCK & CO.: NET SALES ($MILLION)
  • FIGURE 68.SYNGENE INTERNATIONAL LTD.: NET SALES ($MILLION)
  • FIGURE 69.THERMO FISHER SCIENTIFIC, INC..: NET SALES ($MILLION)
  • FIGURE 70.TCG LIFE SCIENCE PVT. LTD.: NET SALES ($MILLION)